U.S. insurers tighten GLP-1 coverage as weight-loss drug costs rise

Traders Union
All News
Financial News
Insurers tighten GLP-1 coverage

Highlights

Commercial insurance coverage for Novo Nordisk's Wegovy will exclude 42% more people in 2026 versus 2025, while Zepbound exclusions will rise 12%.
Employers are shifting weight-loss drug costs to workers as Eli Lilly and Novo Nordisk expand direct-to-consumer and self-pay channels amid rising GLP-1 demand.
KFF estimates 36 million people in employer-sponsored plans could qualify for GLP-1 treatments, highlighting growing cost burdens and increased prior authorization hurdles.

Coverage restrictions expand across employer plans

Patients interviewed in the article describe losing coverage for drugs such as Eli Lilly's Zepbound and Mounjaro, or facing new conditions before benefits can be restored. In one case, coverage for Zepbound ended after an insurer determined the patient did not have diabetes, leaving a six-month monitoring and counseling program as the only possible route back to reimbursement. GoodRx says commercial coverage for Novo Nordisk's Wegovy and Zepbound becomes more restrictive in 2026, with the number of people lacking coverage for Wegovy rising 42% from 2025 to 2026, and the comparable figure for Zepbound increasing 12%.

Drugmakers, employers and patients shift to self-pay options

Rising demand for GLP-1 therapies is increasing pressure on employers, which are already facing higher health insurance costs and are passing more expense on to workers through premiums and less generous plans. The article says Eli Lilly and Novo Nordisk are expanding direct-to-consumer and self-pay channels, while compound pharmacies are also gaining traction among patients who cannot secure insurer approval. Novo Nordisk says self-pay platforms are intended to fill coverage gaps rather than replace insurance-based access, but researchers and physicians cited in the article say many patients are increasingly bypassing insurers to obtain treatment.

Broader implications for U.S. healthcare spending

The article presents GLP-1 reimbursement as part of a wider pattern in which private insurance increasingly limits access to expensive or newer treatments, including cancer therapies, mental healthcare and fertility services. KFF estimates that 36 million people in employer-sponsored plans could qualify for GLP-1 treatment based on body mass index, underscoring the scale of the potential cost burden. Physicians quoted in the article say navigating prior authorizations and denials now consumes substantial clinic time, while patients often face the choice between paying out of pocket, delaying care or seeking less regulated alternatives.

We previously reported on Eli Lilly’s push to strengthen its weight-loss drug leadership through new FDA milestones and major strategic moves. That update highlighted the company’s progress around an oral GLP-1 option, the launch of Foundayo, and a planned acquisition to broaden its pipeline, alongside a TU outlook noting elevated volatility and a likely consolidation range for LLY shares.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.